PDF(Pubmed)
Abstract：
This review emphasises the importance of opioid monitoring in clinical practice and advocates for a personalised approach based on pharmacogenetics. Beyond effectively managing pain, meticulous oversight is required to address concerns about side effects, specially due to opioid-crisis-related abuse and dependence. Various monitoring techniques, along with pharmacogenetic considerations, are critical for personalising treatment and optimising pain relief while reducing misuse and addiction risks. Future perspectives reveal both opportunities and challenges, with advances in analytical technologies holding promise for increasing monitoring efficiency. The integration of pharmacogenetics has the potential to transform pain management by allowing for a precise prediction of drug responses. Nevertheless, challenges such as prominent pharmacogenetic testing and guideline standardisation persist. Collaborative efforts are critical for transforming scientific advances into tangible improvements in patient care. Standardised protocols and interdisciplinary collaboration are required to ensure consistent and evidence-based opioid monitoring. Future research should look into the long-term effects of opioid therapy, as well as the impact of genetic factors on individual responses, to help guide personalised treatment plans and reduce adverse events. Lastly, embracing innovation and collaboration can improve the standard of care in chronic pain management by striking a balance between pain relief and patient safety.
摘要：
这篇综述强调了阿片类药物监测在临床实践中的重要性，并倡导了基于药物遗传学的个性化方法。除了有效控制疼痛，需要细致的监督来解决对副作用的担忧，特别是由于与阿片类药物危机相关的滥用和依赖。各种监测技术，随着药物遗传学的考虑，对于个性化治疗和优化疼痛缓解，同时减少滥用和成瘾风险至关重要。未来的前景揭示了机遇和挑战，随着分析技术的进步，有望提高监测效率。药物遗传学的整合有可能通过精确预测药物反应来改变疼痛管理。然而，诸如突出的药物遗传学测试和指南标准化等挑战仍然存在。合作努力对于将科学进步转化为患者护理的切实改善至关重要。需要标准化的协议和跨学科合作，以确保一致和基于证据的阿片类药物监测。未来的研究应该着眼于阿片类药物治疗的长期影响，以及遗传因素对个体反应的影响，帮助指导个性化治疗计划，减少不良事件。最后,通过在缓解疼痛和患者安全之间取得平衡，拥抱创新和协作可以提高慢性疼痛管理的护理标准。
